PT  - JOURNAL ARTICLE
AU  - Marianne Chapleau
AU  - Leonardo Iaccarino
AU  - David Soleimani-Meigooni
AU  - Gil D. Rabinovici
TI  - The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review
AID  - 10.2967/jnumed.121.263195
DP  - 2022 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 13S--19S
VI  - 63
IP  - Supplement 1
4099  - http://jnm.snmjournals.org/content/63/Supplement_1/13S.short
4100  - http://jnm.snmjournals.org/content/63/Supplement_1/13S.full
SO  - J Nucl Med2022 Jun 01; 63
AB  - Imaging of amyloid deposition using PET has been available in research studies for 2 decades and has been approved for clinical use by the U.S. Food and Drug Administration, the European Medicines Agency, and other regulatory agencies around the world. Amyloid PET is a crucial tool for the diagnosis of Alzheimer disease, as it allows the noninvasive detection of amyloid plaques, a core neuropathologic feature that defines the disease. The clinical use of amyloid PET is expected to increase with recent accelerated approval in the United States of aducanumab, an antiamyloid monoclonal antibody, for the treatment of mild cognitive impairment and mild dementia due to Alzheimer disease. However, amyloid pathology can also be found in cognitively unimpaired older adults and in patients with other neurodegenerative disorders. The aim of this review is to provide an up-to-date overview of the application of amyloid PET in neurodegenerative diseases. We provide an in-depth analysis of the clinical, pathologic, and imaging correlates; a comparison with other available biomarkers; and a review of the application of amyloid PET in clinical trials and clinical utility studies.